Ignite Creation Date:
2024-05-06 @ 12:43 PM
Last Modification Date:
2024-10-26 @ 1:03 PM
Study NCT ID:
NCT03839823
Status:
COMPLETED
Last Update Posted:
2023-06-26
First Post:
2019-01-24
Brief Title:
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
Keywords:
| Name | View |
|---|---|
| HR-positive | View |
| HER2-negative | View |
| advanced breast cancer | View |
| Ribociclib | View |
| NSAI | View |
| Goserelin | View |
| Docetaxel capecitabine | View |
| Paclitaxelgemcitabine | View |
| Capecitabinevinorelbine | View |
| CDK46 inhibitors | View |
| Phase II | View |
| ER-positive | View |
| PR-positive | View |
| Premenopausal | View |
| Perimenopausal | View |